Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nami Hirano"'
Autor:
Chikako Funasaka, Akiko Hanai, Sadamoto Zenda, Keita Mori, Makoto Fukui, Nami Hirano, Rie Shinohara, Nozomu Fuse, Masashi Wakabayashi, Mai Itagaki, Yutaka Tomioka, Michihiko Nishina, Yasuaki Arai, Takahiro Kogawa, Yukinori Ozaki, Meiko Nishimura, Takayuki Kobayashi, Fumikata Hara, Toshimi Takano, Toru Mukohara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is one of the most common adverse events that can significantly impair the quality of life of patients. Although limb cooling may be beneficial for preventing CIPN, logistical challenges exi
Externí odkaz:
https://doaj.org/article/e1de7bd468ee4989bc20236eaa2dcef1
Autor:
Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino, Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Yoshito Komatsu, Eiji Shinozaki, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Background BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expres
Externí odkaz:
https://doaj.org/article/d4dc360f8caa4a12beca9ac3e971093a
Autor:
Masashi Wakabayashi, Yumiko Saito, Chin Keisho, Akihiro Sato, Nami Hirano, Hitomi Tamura, Yoshiaki Nakamura, Takashi Ikeno, Akihito Kawazoe, Moe Kambe, Kohei Shitara, Miki Fukutani, Daisuke Takahari, Shogo Nomura
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 24(1)
This is a phase 2 study aimed at evaluating the efficacy and safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 in patients with advanced gastric cancer (AGC). Eligible patients had AGC with measurable lesions, accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8e587b0fe8839a00ddd97802b79f0f
https://pubmed.ncbi.nlm.nih.gov/32700159
https://pubmed.ncbi.nlm.nih.gov/32700159
Autor:
Takashi Kojima, Masako Asayama, Yosuke Togashi, Yuichi Mikamoto, Naoki Takahashi, Masashi Wakabayashi, Akihito Kawazoe, Hitomi Tamura, Nami Hirano, Shota Fukuoka, Akihiro Sato, Takeshi Kuwata, Kohei Shitara, Takako Yoshii, Shogo Nomura, Hiroyoshi Nishikawa, Daisuke Kotani, Hiroki Hara
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(18)
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c1dd87d832f6e56032b18e7380fbff3
https://pubmed.ncbi.nlm.nih.gov/32398704
https://pubmed.ncbi.nlm.nih.gov/32398704
Autor:
Takayuki Yoshino, Daisuke Kotani, Hiroya Taniguchi, Taroh Satoh, Noriko Fujishiro, Nozomu Fuse, A. Ohtsu, Koji Takahashi, Eiji Shinozaki, Tomohiro Nishina, Yoshito Komatsu, Hideaki Bando, Akihiro Sato, Shogo Nomura, Takako Eguchi Nakajima, Toshiki Masuishi, Nami Hirano, Taito Esaki, Hiromi Ono, Masashi Wakabayashi
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
ESMO Open
ESMO Open
Background BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a515280a0923e496533849c83f789e03
https://esmoopen.bmj.com/content/4/6/e000590.full
https://esmoopen.bmj.com/content/4/6/e000590.full
Autor:
Yasutoshi Kuboki, Hiroyoshi Nishikawa, Takayuki Yoshino, Shogo Nomura, Satoshi Yuki, Eiji Shinozaki, Yosuke Togashi, Akihiro Sato, Tomohiro Nishina, Hiroki Hara, Yoshito Komatsu, Atsushi Ohtsu, Yuichi Mikamoto, Nami Hirano, Akihito Kawazoe, Koji Takahashi
Publikováno v:
Journal of Clinical Oncology. 38:107-107
107 Background: The anti–PD-1 antibody pembrolizumab (P) provides response rates of 28-57% in patients (pts) with MSI-H metastatic colorectal cancer (mCRC) vs 0% in those with non-MSI-H cancers. STAT3 has been previously reported as a potential key
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad68e5a0459e6c7b519f485158b366f3
https://doi.org/10.1200/jco.2020.38.4_suppl.107
https://doi.org/10.1200/jco.2020.38.4_suppl.107
Autor:
Takashi Kojima, Hitomi Tamura, Masashi Wakabayashi, Yuichi Mikamoto, Hiroyoshi Nishikawa, Akihito Kawazoe, Kohei Shitara, Takako Yoshii, Shogo Nomura, Nami Hirano, Naoki Takahashi, Shota Fukuoka, Akihiro Sato, Masako Asayama, Hiroki Hara, Daisuke Kotani
Publikováno v:
Journal of Clinical Oncology. 38:135-135
135 Background: In the phase 1 REGONIVO study, regorafenib of 80 mg/day plus nivolumab showed manageable safety profiles and encouraging anti-tumor activity for advanced colorectal cancer (CRC) or gastric cancer (GC) with objective response rate (ORR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54f007e4f6c46f7c443d830fb24118f7
https://doi.org/10.1200/jco.2020.38.4_suppl.135
https://doi.org/10.1200/jco.2020.38.4_suppl.135
Autor:
Keisuke Hori, Atushi Ohtsu, Yasuhiro Shirakawa, Toshiyoshi Fujiwara, Shogo Nomura, Hiroyoshi Nishikawa, Yosuke Togashi, Nami Hirano, Masako Nakamoto, Akihiro Sato, Toshihiko Doi, Hiromi Ono, Takashi Kojima, Masashi Wakabayashi
Publikováno v:
Cancer Research. 79:CT024-CT024
Background: PD-1 blockade showed promising efficacy for broad type of cancer patients (pts), though objective response rates are very limited. The antitumor potential of oncolytic adenoviruses has been demonstrated in preclinical and clinical studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1044347be68336f441f9b53b43df1ba
https://doi.org/10.1158/1538-7445.am2019-ct024
https://doi.org/10.1158/1538-7445.am2019-ct024
Autor:
Eiji Shinozaki, Akihito Kawazoe, Yasutoshi Kuboki, Yoshito Komatsu, Tomohiro Nishina, Hiroki Hara, Satoshi Yuki, Kohei Shitara, Hideaki Bando, Daisuke Kotani, Koji Takahashi, Yuichi Mikamoto, Hiromi Hasegawa, Nami Hirano, Shogo Nomura, Yosuke Togashi, Hiroyoshi Nishikawa, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
Publikováno v:
Journal of Clinical Oncology. 36:3530-3530
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9a6baf7898dcefaf89830986a12d1e0
https://doi.org/10.1200/jco.2018.36.15_suppl.3530
https://doi.org/10.1200/jco.2018.36.15_suppl.3530
Autor:
Yasutoshi Kuboki, Akihito Kawazoe, Yoshito Komatsu, Tomohiro Nishina, Eiji Shinozaki, Hiroki Hara, Satoshi Yuki, Miki Fukutani, Natsuko Tsukahara, Hiromi Hasegawa, Nami Hirano, Shogo Nomura, Yosuke Togashi, Hiroyoshi Nishikawa, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino
Publikováno v:
Journal of Clinical Oncology. 35:TPS3623-TPS3623
TPS3623 Background: Immune checkpoint inhibitor (ICI) was reported to show durable responses in patients with MSI-H (Microsatellite Instability-High) metastatic colorectal cancer (mCRC). On the other hand, for patients with MSS (Microsatellite Stable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d79a7eae4e4e820e55de3efbb9045989
https://doi.org/10.1200/jco.2017.35.15_suppl.tps3623
https://doi.org/10.1200/jco.2017.35.15_suppl.tps3623